4CPS-103 Second-generation tyrosin kinase inhibitors in front-line therapy. comparing responses
CM Valencia Soto(Hospital La Inmaculada), S Cortes-de Miguel(Hospital La Inmaculada), MV Villacañas-Palomares, R López-Sepúlveda(Hospital Universitario Virgen de las Nieves), P Nieto Gómez(Instituto de Investigación Biosanitaria de Granada), F Artime-Rodríguez-Hermida(Hospital Universitario Virgen de las Nieves), Sabrina Herrera(Mayo Clinic)
Cited by 0
Related Papers
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
|Clinical Cancer Research|2015|119
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
|Breast Cancer Research and Treatment|2017|95
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase
|Breast Cancer Research|2014|70
Systematic Review of Microthrombi in COVID-19 Autopsies
|Acta Haematologica|2021|62